射血分数降低的心力衰竭患者的中西药治疗研究进展

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (488 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract According to the level of left ventricular ejection fraction (LVEF), heart failure (HF) can be divided into heart failure with reduced ejection fraction (HFrEF), heart failure with retained ejection fraction (HFpEF) and heart failure with median ejection fraction (HFmrEF). HFrEF is the main type of HF, and its incidence is increasing year by year. Although the combination of existing traditional drugs for the treatment of HFrEF can delay the course of the disease and improve the symptoms and prognosis of patients to a certain extent, there are many adverse reactions of traditional drugs, the treatment effect of HFrEF is limited, and the complications or complications of HFrEF can not be effectively treated, and the rehospitalization rate and mortality rate of patients are still high. Recently, with the further research and exploration of the occurrence and development of HFrEF and the mechanism of drug action, a variety of Chinese and Western drugs have been developed to make up for the deficiency of traditional drugs in the treatment of HFrEF.In this paper,the treatment of HFrEF Chinese and Western medicine representative drugs Ivabradine,Shakubaqu Valsartan, Aliskiren, Shexiang Baoxin Pills, Qili QiangXin Capsule pharmacological characteristics and treatment progress were reviewed.

Key words： Heart failure with reduced ejection fraction Treatment Western medicine Chinese medicine Research progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Z HOU Ling
	LI Huabo

Cite this article:

Z HOU Ling,LI Huabo. Research progress of Chinese and Western medicine treatment of patients with heart failure with reduced ejection fraction[J]. 中国当代医药, 2022, 29(4): 29-32.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I4/29

[15]	Luo Y，Chen Q.Efficacy of aliskiren supplementation for heart failure[J].Herz，2019，44（12）：398-404.
[18]	宿敏，赵信科，蒋虎刚，等.益气活血利水法治疗慢性心力衰竭合并贫血概述[J].实用中医内科杂志，2021，10（1）：92-95.
[19]	刘宗昆.周立华教授治疗慢性充血性心力衰竭病经验总结[D].郑州：河南中医药大学，2018.
[20]	尚辉，李剑锋.麝香保心丸辅助西药治疗原发性高血压合并心力衰竭的效果[J].河南医学研究，2021，30（6）：1094-1096.
[21]	王振兴，刘志超，高晟玮，王保和.麝香保心丸作用机制研究进展[J].中国中医急症，2020，29（7）：1309-1312.
[22]	史云桃，王用.芪苈强心胶囊对冠心病合并心力衰竭患者短期疗效观[J].中华老年心脑血管病杂志，2018，20（9）：986-987.
[23]	李立凤，杨志华，王居平，等.芪苈强心胶囊治疗慢性充血性心力衰竭作用机制的网络药理学研究[J].长治医学院学报，2021，35（2）：89-94.
[1]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[2]	王宙，周琳，刘洋，等.慢性心力衰竭的流行病学研究现状及其防治研究进展[J].中国循证心血管医学杂志，2019，11（8）：1022-1024.
[13]	崔晓通，周京敏，葛均波.PARADIGM-HF 研究结果解读[J].中国循环杂志，2018，33（2）：203-205.
[3]	Bosco-Lévy P，Favary C，Jové J，et al.Pharmacological treatment patterns in heart failure：a population-based cohort study[J].Eur J Clin Pharmacol，2020，76（12）：97-106.
[4]	Chen C，Kaur G，Mehta PK，et al.Ivabradine in Cardiovascular Disease Manage-ment Revisited：a Review[J].Cardiovasc Drugs Ther，2021，11（5）：25-33.
[5]	Maagaard M，Nielsen EE，Gluud C，et al.Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with metaanalysis and Trial Sequential Analysis[J].Syst Rev，2019，8（11）：39-41.
[6]	Kiuchi S，Hisatake S，Kabuki T，et al.Efficacy and Safety of Ivabradine in an Elderly Patient with Heart Failure with Reduced Ejection Fraction[J].Clin Drug Investig，2021，41（13）：193-196.
[7]	Komajda M，Isnard R，Cohen-Solal A，et al.Effect of ivabradine in patients with heart failure with preserved ejection fraction：the EDIFY randomized placebocontrolled trial[J].Eur J Heart Fail，2017，19（11）：1495-1503.
[8]	Gregorietti V，Fernandez TL，Costa D，et al.Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy[J].CardioOncology，2020，6（12）：24-26.
[9]	Polito MV，Silverio A，Rispoli A，et al.Clinical and echocardiographic benefit of Sacubitril/valsartan in a realworld population with HF with reduced ejection fraction[J].Sci Rep，2020，10（1）：6665.
[10]	Moliner-Abós C，Rivas-Lasarte M，Pamies Besora J，et al.Sacubitril/valsartan in real-life practice：experience in patients with advanced heart failure and systematic review[J].Cardiovasc Drugs Ther，2019，33（3）：307-314.
[11]	Sauer AJ，Cole R，Jensen BC，et al.Practical guidance on the use of sacubitril/valsartan for heart failure[J].Heart Fail Rev，2019，24（10）：167-176.
[12]	De Vecchis R，Paccone A，Di Maio M.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction[J].Herz，2019，44（15）：425-432.
[14]	Gaziano TA，Fonarow GC，Velazquez EJ，et al.Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction[J].JAMA Cardiol，2020，5（11）：1236-1244.
[16]	Kristensen SL，Mogensen UM，Tarnesby G，et al.Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes：a subgroup analysis from the ATMOSPHERE trial[J].Eur J Heart Fail，2017，20（1）：136-147.
[17]	Zhao Q，Shen J，Lu J，et al.Clinical efficacy，safety and tolerability of Aliskiren Monotherapy （AM）：an umbrella review of systematic reviews[J].BMC Cardiovasc Disord，2020，20（2）：179-182.
[24]	林冰冰，王雳，叶靖.芪苈强心胶囊联合新型ARNI 对慢性心力衰竭患者血浆NT-proBNP、Ang-Ⅱ、ALD、血清MMP-9 水平及心功能的影响[J].临床合理用药杂志，2021，14（13）：13-15.
[25]	李红娟，左征，刘海漫，等.芪苈强心胶囊联合心脏康复训练治疗心脏瓣膜病合并心力衰竭疗效及对NT-proBNP、TNF-α、IL-6 水平的影响[J].现代中西医结合杂志，2021，30（16）：1804-1807.
[26]	张艳佩.芪苈强心胶囊联合西药在慢性心力衰竭患者中的应用价值[J].河南医学研究，2021，30（5）：927-929.